Family studies in Crohn's disease: New horizons in understanding disease pathogenesis, risk and prevention

Gut

Volumn 61, Issue 2, 2012, Pages 311-318

  Hedin, Charlotte R ^a,b   Stagg, Andrew J ^b   Whelan, Kevin ^a   Lindsay, James O ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; C REACTIVE PROTEIN; CALGRANULIN; FUNGUS ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY BLOOD LEVEL; CHRONIC INFLAMMATION; CROHN DISEASE; FAMILY STUDY; FECES LEVEL; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOME ANALYSIS; HIGH RISK POPULATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT;

BIOLOGICAL MARKERS; CROHN DISEASE; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; INTESTINAL MUCOSA; PHENOTYPE; PROGNOSIS; RISK FACTORS;

EID: 84855206901     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2011.238568     Document Type: Review

References (94)

1. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010;105:289-97.
2. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol 2003;98:1064-72. (Pubitemid 36733768)
3. Perminow G, Brackmann S, Lyckander LG, et al. A characterization in childhood inflammatory bowel disease, a new population-based inception cohort from South-Eastern Norway, 2005e07, showing increased incidence in Crohn's disease. Scand J Gastroenterol 2009;44:446-56.
4. Packey CD, Sartor RB. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. Curr Opin Infect Dis 2009;22:292-301.
5. Probert CSJ, Jayanthi V, Hughes AO, et al. Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and South Asians in Leicestershire. Gut 1993;34:1547-51. (Pubitemid 23341846)
6. Bennett RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology 1991;100:1638-43.
7. Visscher PM, Hill WG, Wray NR. Heritability in the genomics eradconcepts and misconceptions. Nat Rev Genet 2008;9:255-66.
8. Tysk C, Lindberg E, Jarnerot G, et al. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988;29:990-6.
9. Halfvarson J, Jess T, Bodin L, et al. Longitudinal concordance for clinical characteristics in a SwedisheDanish twin population with inflammatory bowel disease. Inflamm Bowel Dis 2007;13:1536-44.
10. Weersma RK, Stokkers PC, van Bodegraven AA, et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut 2009;58:388-95.
11. Halfvarson J. Genetics in twins with Crohn's disease: less pronounced than previously believed? Inflamm Bowel Dis 2011;17:6-12.
12. Hampe J, Heymann K, Krawczak M, et al. Association of inflammatory bowel disease with indicators for childhood antigen and infection exposure. Int J Colorectal Dis 2003;18:413-17. (Pubitemid 37062732)
13. Bridger S, Lee JC, Bjarnason I, et al. In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn's disease and non-smokers develop ulcerative colitis. Gut 2002;51:21-5. (Pubitemid 34717738)
14. Barclay AR, Russell RK, Wilson ML, et al. Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. J Pediatr 2009;155:421-6.
15. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-3. (Pubitemid 44871953)
16. WTCCC. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-78.
17. Hugot JP, Zaccaria I, Cavanaugh J, et al. Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am J Gastroenterol 2007;102:1259-67. (Pubitemid 46802011)
18. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-25.
19. Park JH, Wacholder S, Gail MH, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet 2010;42:570-5.
20. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009;461:747-53.
21. Goldstein DB. Common genetic variation and human traits. N Engl J Med 2009;360:1696-8.
22. Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 2010;141:1135-45.
23. Gibson G. Hints of hidden heritability in GWAS. Nat Genet 2010;42:558-60.
24. Bjarnason I, O'Morain C, Levi AJ, et al. Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 1983;85:318-22. (Pubitemid 13070915)
25. Miki K, Moore DJ, Butler RN, et al. The sugar permeability test reflects disease activity in children and adolescents with inflammatory bowel disease. J Pediatr 1998;133:750-4. (Pubitemid 28563943)
26. Peeters M, Ghoos Y, Maes B, et al. Increased permeability of macroscopically normal small bowel in Crohn's disease. Dig Dis Sci 1994;39:2170-6. (Pubitemid 24341630)
27. Van der Sluis M, De Koning BA, De Bruijn AC, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006;131:117-29. (Pubitemid 44015753)
28. Olson TS, Reuter BK, Scott KG, et al. The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med 2006;203:541-52.
29. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40:955-62.
30. Hollander D, Vadheim CM, Brettholz E, et al. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 1986;105:883-5. (Pubitemid 17201765)
31. Munkholm P, Langholz E, Hollander D, et al. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut 1994;35:68-72. (Pubitemid 24059475)
32. May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn's disease? Gastroenterology 1993;104:1627-32. (Pubitemid 23235451)
33. Yacyshyn BR, Meddings JB. CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeability. Gastroenterology 1995;108:132-7.
34. Soderholm JD, Olaison G, Lindberg E, et al. Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence? Gut 1999;44:96-100. (Pubitemid 29143287)
35. Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001;7:8-15.
36. Buhner S, Buning C, Genschel J, et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut 2006;55:342-7. (Pubitemid 43268271)
37. D'Inca R, Annese V, di Leo V, et al. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease. Aliment Pharmacol Ther 2006;23:1455-61.
38. Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology 2000;119:1740-4. (Pubitemid 32198699)
39. Rabbani GH, Teka T, Saha SK, et al. Green banana and pectin improve small intestinal permeability and reduce fluid loss in Bangladeshi children with persistent diarrhea. Dig Dis Sci 2004;49:475-84. (Pubitemid 38453569)
40. Schepens MA, Rijnierse A, Schonewille AJ, et al. Dietary calcium decreases but short-chain fructo-oligosaccharides increase colonic permeability in rats. Br J Nutr 2010;104:1780-6.
41. Roberts CL, Keita AV, Duncan SH, et al. Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut 2010;59:1331-9.
42. Kelly LM, Benjamin JL, Koutsoumpas A, et al. Dietary fructo- oligosaccharide intakes in patients with active Crohn's disease. J Hum Nutr Diet 2010;23:323.
43. Hedin CR, Mullard M, Sharratt E, et al. Probiotic and prebiotic use in patients with inflammatory bowel disease: a caseecontrol study. Inflamm Bowel Dis 2010;16:2099-108.
44. Catassi C, Bonucci A, Coppa GV, et al. Intestinal permeability changes during the first month: effect of natural versus artificial feeding. J Pediatr Gastroenterol Nutr 1995;21:383-6.
45. Ehrchen JM, Sunderkotter C, Foell D, et al. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009;86:557-66.
46. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13.
47. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369.
48. Thjodleifsson B, Sigthorsson G, Cariglia N, et al. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology 2003;124:1728-37. (Pubitemid 36666769)
49. D'Incà R, Oliva L, Latiano A, et al. Intestinal permeability, fecal calprotectin and CARD 15 mutations in first degree relatives of Crohn's disease patients. Gastroenterology 2008;134: A497-8.
50. Pham M, Leach ST, Lemberg DA, et al. Subclinical intestinal inflammation in siblings of children with Crohn's disease. Dig Dis Sci 2010;55:3502-7.
51. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22. (Pubitemid 30452574)
52. Elmgreen J, Both H, Binder V. Familial occurrence of complement dysfunction in Crohn's disease: correlation with intestinal symptoms and hypercatabolism of complement. Gut 1985;26:151-7. (Pubitemid 15105141)
53. Peyrin-Biroulet L, Standaert-Vitse A, Branche J, et al. IBD serological panels: facts and perspectives. Inflamm Bowel Dis 2007;13:1561-6.
54. Klebl FH, Bataille F, Bertea CR, et al. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm Bowel Dis 2003;9:302-7. (Pubitemid 37161749)
55. Konrad A, Rutten C, Flogerzi B, et al. Immune sensitization to yeast antigens in ASCA-positive patients with Crohn's disease. Inflamm Bowel Dis 2004;10:97-105. (Pubitemid 38332168)
56. Teml A, Kratzer V, Schneider B, et al. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol 2003;98:2226-31. (Pubitemid 37305363)
57. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005;54:1232-6. (Pubitemid 41192480)
58. Annese V, Andreoli A, Andriulli A, et al. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am J Gastroenterol 2001;96:2407-12. (Pubitemid 32769203)
59. Glas J, Torok HP, Vilsmaier F, et al. Anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease and their first-degree relatives: potential clinical value. Digestion 2002;66:173-7. (Pubitemid 36096844)
60. Seibold F, Boldt AB, Seibold-Schmid B, et al. Association of deficiency for mannan-binding lectin with anti-mannan antibodies in Crohn's disease: a family study. Inflamm Bowel Dis 2007;13:1077-82. (Pubitemid 47402590)
61. Lindberg E, Magnusson KE, Tysk C, et al. Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. Gut 1992;33:909-13.
62. Mei L, Targan SR, Landers CJ, et al. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology 2006;130:1078-85.
63. Cruyssen BV, Peeters H, Hoffman IE, et al. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients. Clin Exp Immunol 2005;140:354-9. (Pubitemid 40559164)
64. Devlin SM, Yang H, Ippoliti A, et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology 2007;132:576-86. (Pubitemid 46274655)
65. Walker LJ, Aldhous MC, Drummond HE, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 2004;135:490-6. (Pubitemid 38297152)
66. Halfvarson J, Standaert-Vitse A, Jarnerot G, et al. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut 2005;54:1237-43. (Pubitemid 41192481)
67. Joossens S, Vermeire S, Van SK, et al. Pancreatic autoantibodies in inflammatory bowel disease. Inflamm Bowel Dis 2004;10:771-7. (Pubitemid 39545223)
68. Folwaczny C, Noehl N, Endres SP, et al. Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives. Dig Dis Sci 1997;42:1593-7. (Pubitemid 27394579)
69. Fiocchi C, Roche JK, Michener WM. High prevalence of antibodies to intestinal epithelial antigens in patients with inflammatory bowel disease and their relatives. Ann Intern Med 1989;110:786-94. (Pubitemid 19128996)
70. Folwaczny C, Noehl N, Tschop K, et al. Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterology 1997;113:101-6. (Pubitemid 27281763)
71. Kraus TA, Toy L, Chan L, et al. Failure to induce oral tolerance in Crohn's and ulcerative colitis patients: possible genetic risk. Ann NY Acad Sci 2004;1029:225-38. (Pubitemid 40298533)
72. Kraus TA, Cheifetz A, Toy L, et al. Evidence for a genetic defect in oral tolerance induction in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:82-8.
73. Indaram AV, Nandi S, Weissman S, et al. Elevated basal intestinal mucosal cytokine levels in asymptomatic first-degree relatives of patients with Crohn's disease. World J Gastroenterol 2000;6:49-52. (Pubitemid 30093061)
74. Efrat B, Iris G, Wang H, et al. A subgroup of first-degree relatives of Crohn's disease patients shows a profile of inflammatory markers in the blood which is more typical of Crohn's disease patients than of normal individuals. Mediators Inflamm 2006;2006:74785.
75. Hart AL, Kamm MA, Knight SC, et al. Quantitative and functional characteristics of intestinal-homing memory T cells: analysis of Crohn's disease patients and healthy controls. Clin Exp Immunol 2004;135:137-45. (Pubitemid 38067938)
76. Meenan J, Spaans J, Grool TA, et al. Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation. Gut 1997;40:241-6. (Pubitemid 27093101)
77. Schmechel S, Konrad A, Diegelmann J, et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis 2008;14:204-12. (Pubitemid 351288041)
78. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29. (Pubitemid 34851835)
79. Tamboli CP, Neut C, Desreumaux P, et al. Dysbiosis in inflammatory bowel disease. Gut 2004;53:1-4. (Pubitemid 38082999)
80. Zoetendal EG, Akkermans AD, De Vos WM. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 1998;64:3854-9. (Pubitemid 28462983)
81. Sokol H, Seksik P, Furet JP, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009;15:1183-9.
82. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008;105:16731-6.
83. Neut C, Sivignon A, Joossens M, et al. The Crohn's disease associated NOD2 mutations predispose to dysbiosis. Gastroenterology 2007;132:T1764.
84. Joossens M, Huys G, Cnockaert M, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011;60:631-7.
85. Stewart JA, Chadwick VS, Murray A. Investigations into the influence of host genetics on the predominant eubacteria in the faecal microflora of children. J Med Microbiol 2005;54:1239-42. (Pubitemid 41783834)
86. Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010;139:1844-54.
87. Dicksved J, Halfvarson J, Rosenquist M, et al. Molecular analysis of the gut microbiota of identical twins with Crohn's disease. ISME J 2008;2:716-27. (Pubitemid 351951567)
88. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480-4.
89. Visscher PM, Medland SE, Ferreira MA, et al. Assumption-free estimation of heritability from genome-wide identity-by-descent sharing between full siblings. PLoS Genet 2006;2:-41.
90. Berstad A, Arslan G, Folvik G. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. Scand J Gastroenterol 2000;35:64-9. (Pubitemid 30066774)
91. Torok HP, Glas J, Hollay HC, et al. Serum antibodies in first-degree relatives of patients with IBD: a marker of disease susceptibility? A follow-up pilot-study after 7 years. Digestion 2005;72:119-23. (Pubitemid 41507271)
92. Joossens M, Van SK, Branche J, et al. Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease. Inflamm Bowel Dis 2010;16:58-67.
93. Joshi S, Lewis SJ, Creanor S, et al. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem 2010;47:259-63.
94. Woodmansey EJ, McMurdo ME, Macfarlane GT, et al. Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects. Appl Environ Microbiol 2004;70:6113-22. (Pubitemid 39471860)